Week in Review: LianBio Acquires Two IBD Candidates in $218 Million Deal

Deals and Financings   LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two IBD candidates from Landos Biopharma in a $218 million deal; Ji Xing Pharma of  Shanghai  announced a $127.5 million agreement for China rights to a novel tachycardia treatment from Milestone Pharma; Singapore 's Hummingbird Bioscience closed a $125 million Series C financing round for novel precision candidates using difficult-to-drug targets; Duality Biologics, an innovative China-US biotech company, raised $90 million in a Series B financing for bispecific and ADC candidates; GeneQuantum Healthcare ( Suzhou ) closed a Series C funding of at least $50 million to develop its portfolio of site-specific ADC molecules; Suzhou BioNovoGene completed a $15 million Series A funding to support its metabolomics services including mass spectrometry test kits; BioRay Pharmaceutical, a Taizhou biotech, in-licensed rights to a Nascent Bio brain cancer candidate in a $5 million deal; Company News CARsgen Therapeutics of  Shanghai  will invest $157 million in a combination CAR-T R&D lab and manufacturing site in  Durham ,  North Carolina ; Trials and Approvals Beijing 's BeiGene said its anti-PD-1 drug, tislelizumab, met its endpoints in a Phase III trial as a first-line therapy for nasopharyngeal cancer; Beijing 's Burning Rock Biotech started a large pan-cancer early-detection study in  China enrolling 12,000 people and using a multi-omics approach; Beijing 's InnoCare reported  China  approved a Phase I trial of its novel oral Tyrosine Kinase 2 inhibitor. Stock Symbols: (NSDQ: LABP) (NSDQ: MIST) (NSDQ: BGNE; HK: 06160) (NSDQ: BNR) (HK: 09969) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.